Asymmetric synthesis method of dezocine key intermediate

A synthesis method and intermediate technology, applied in the field of synthesis of pharmaceutical compounds, can solve the problem that the racemization resolution process cannot be advanced, and achieve the effects of low cost, simple steps and mild conditions

Active Publication Date: 2018-07-20
YANGTZE RIVER PHARM GRP CO LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] Although (5R,11S)-5,6,7,8,9,10,11,12-octahydro-3-methoxy-5-methyl-5,11- Methylenebenzocyclodecen-13-one can avoid the pollution and cost caused by racemic resolution and low-selectivity asymmetric synthesis process, and greatly improve production efficiency; but high stereoselective synthesis (5R,11S)- 5,6,7,8,9,10,11,12-Octahydro-3-methoxy-5-methyl-5,11-methylenebenzocyclodecen-13-one (Compound 3) There are two: on the one hand, in the structure of (1R)-1-(5-bromopentyl)-7-methoxy-1-methyl-tetralone (compound 2), it contains an all-carbon chiral qua

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Asymmetric synthesis method of dezocine key intermediate
  • Asymmetric synthesis method of dezocine key intermediate
  • Asymmetric synthesis method of dezocine key intermediate

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0052] Example 1

[0053] (1R)-1-(5-Bromopentyl)-7-methoxy-1-methyl-tetralone

[0054] In a 250ml three-necked flask, add 7-methoxy-1-methyl-2-tetralone (2.5g, 13mmol), 1,5-dibromopentane (7.55g, 32.8mmol), cinchoni Butane derivative catalyst (0.75g, 1.3mmolR is 2,4-difluorobenzyl, X is Br) and methyl tert-butyl ether (150ml, 55V), protected by nitrogen and protected from light, add 40wt% of KOH aqueous solution (KOH 7.3g, 130mmol), the reaction temperature is controlled at 5-15℃, after 3 hours of reaction, the liquids are separated, the aqueous phase is extracted three times with methyl tert-butyl ether (10ml each time), and the organic phases are combined with 3% The organic phase was washed with HCl; the aqueous phase was discarded, and the organic phase was washed with saturated NaCl solution to pH=7.0-8.0; the organic phase was dried with anhydrous sodium sulfate. Concentrate under reduced pressure to obtain 3.4 g of oily substance with a yield of 78%; [α] D 20 =+24(c=1.0.CH...

Example Embodiment

[0057] Example 2

[0058] (1R)-1-(5-Bromopentyl)-7-methoxy-1-methyl-tetralone

[0059] In a 500ml three-necked flask, add 7-methoxy-1-methyl-2-tetralone (5.0g, 26.3mmol), 1,5-dibromopentane (15.1g, 65.7mmol), and Sink Nidin derivative catalyst (0.75g, 1.3mmol, R is 2-fluoro-4-trifluoromethylbenzyl, X is BF 4 ) And dichloromethane (150ml, 30V), protected by nitrogen and protected from light, add 10wt% LiOH aqueous solution (LiOH 9.4g, 394.5mmol) dropwise, the reaction temperature is controlled at 5-15℃, after 6h reaction, liquid separation , The aqueous phase was extracted three times with dichloromethane (25ml each time), the organic phases were combined, and the organic phase was washed with 1% HCl; the aqueous phase was discarded, and the organic phase was washed with saturated NaCl solution to pH=7.0-8.0; anhydrous sodium sulfate Dry the organic phase. Concentrate under reduced pressure to obtain 6.7 g of oily substance with a yield of 76%; [α] D 20 =+25(c=1.0.CHC1 3 ), the ee...

Example Embodiment

[0060] Example 3

[0061] (1R)-1-(5-Bromopentyl)-7-methoxy-1-methyl-tetralone

[0062] In a 5L three-necked flask, add 7-methoxy-1-methyl-2-tetralone (50g, 263mmol), 1,5-dibromopentane (151g, 657.5mmol), cinchonidine derivative Compound catalyst (14.1g, 26.3mmol, R is 3-fluoro-4-trifluoromethylbenzyl, X is Br) and toluene (1.65L, 35V), protected by nitrogen and protected from light, add 30wt% of CsOH aqueous solution (CsOH 587g, 3.945mol), the reaction temperature is controlled at 10-15℃, after reacting for 1h, the liquids are separated, the aqueous phase is extracted three times with toluene (250ml each time), the organic phases are combined, and the organic phases are washed with 5% HCl 2 Times; discard the water phase, wash the organic phase with saturated NaCl solution to pH=7.0-8.0; dry the organic phase with anhydrous sodium sulfate. Concentrated under reduced pressure to obtain 72.2g of oily substance with a yield of 81%; [α] D 20 =+23(c=1.0.CHC1 3 ), the ee value of 78% d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Melting pointaaaaaaaaaa
Login to view more

Abstract

The invention discloses an asymmetric synthesis method of a dezocine key intermediate, namely, (5R,11S)-5,6,7,8,9,10,11,12-octahydro-3-methoxy-5-methyl-5,11-methylenebenzocyclodecene-13-one. The synthesis method comprises the steps as follows: 7-methoxy-1-methyl-2-tetralone is adopted as a raw material, and an alkylation reaction intermediate, namely, (1R)-1-(5-bormopentyl)-7-methoxy-1-methyl-tetralone, is synthesized in a stereoselective manner under the catalysis of a cinchonidine derivative; ring formation under the alkaline action is performed, and (5R,11S)-5,6,7,8,9,10,11,12-octahydro-3-methoxy-5-methyl-5,11-methylenebenzocycldecene-13-one with high chiral purity is obtained through recrystallization. The method is high in reaction yield, low in cost, mild in condition and suitable for efficient synthesis of dezocine on a large scale.

Description

technical field [0001] The present invention relates to the synthesis of pharmaceutical compounds, in particular to the key intermediate (5R,11S)-5,6,7,8,9,10,11,12-octahydro-3-methoxy- Asymmetric synthesis of 5-methyl-5,11-methylenebenzocyclodecen-13-one. Background technique [0002] Dezocine, English name Dezocine, chemical name (-)-[5R-(5α,11α,13S*)]-13-amino-5,6,7,8,9,10,11,12-octahydro -5-methyl-5,11-methylenebenzocyclodecen-3-ol, the chemical structural formula is as shown in I: [0003] [0004] Dezocine, developed by Astrazeneca, is a potent opioid analgesic that mainly acts on μ and κ receptors. The analgesic effect of dezocine is equivalent to that of morphine, with less addiction and milder adverse reactions than similar drugs. It is suitable for the treatment of moderate to severe pain after surgery, visceral colic and pain in patients with advanced cancer. One of the most widely used drugs for analgesia. [0005] There are three consecutive chiral center...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07C45/68C07C49/755C07C45/67C07B53/00
CPCC07B53/00C07B2200/07C07C45/67C07C45/673C07C45/68C07C49/755
Inventor 黄翔徐镜人肖志超要世伟蔡伟任中杰张海波袁晓林王佩强张小军
Owner YANGTZE RIVER PHARM GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap